The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-[2-(1,1-dioxo-1,4-thiazinan-4-yl)pyrimidin-4-yl]-3-(4-methoxyphenyl)isoxazol-5-amine ID: ALA5091264
PubChem CID: 156380044
Max Phase: Preclinical
Molecular Formula: C18H19N5O4S
Molecular Weight: 401.45
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc(-c2cc(Nc3ccnc(N4CCS(=O)(=O)CC4)n3)on2)cc1
Standard InChI: InChI=1S/C18H19N5O4S/c1-26-14-4-2-13(3-5-14)15-12-17(27-22-15)20-16-6-7-19-18(21-16)23-8-10-28(24,25)11-9-23/h2-7,12H,8-11H2,1H3,(H,19,20,21)
Standard InChI Key: FKCWKAFUIGJYET-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
8.0790 -5.0497 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1330 -4.3624 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.4944 -3.2502 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
8.6637 -3.2502 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.0251 -4.3624 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.1547 -4.6651 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
10.9817 -3.8381 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.6793 -2.7083 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.5046 -1.8845 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.6346 -2.1873 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.9380 -3.3108 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1163 -4.1421 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.0677 -3.6135 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
14.8947 -2.7866 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0243 -3.0893 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.3270 -4.2190 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
15.5001 -5.0459 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3704 -4.7432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4567 -4.5217 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
16.6297 -5.3486 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.0034 -4.6651 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7003 -5.7948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.5737 -6.0955 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.7465 -5.2683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.0455 -4.1436 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1728 -3.8346 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6168 -5.5710 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.7898 -4.7440 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
4 5 1 0
5 1 2 0
5 6 1 0
6 7 1 0
8 7 2 0
9 8 1 0
10 9 2 0
11 10 1 0
12 11 2 0
7 12 1 0
13 11 1 0
13 14 1 0
15 14 1 0
16 15 1 0
17 16 1 0
18 17 1 0
13 18 1 0
16 19 2 0
16 20 2 0
21 2 1 0
22 21 2 0
23 22 1 0
24 23 2 0
25 24 1 0
26 25 2 0
21 26 1 0
24 27 1 0
27 28 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 401.45Molecular Weight (Monoisotopic): 401.1158AlogP: 2.12#Rotatable Bonds: 5Polar Surface Area: 110.45Molecular Species: NEUTRALHBA: 9HBD: 1#RO5 Violations: ┄HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 8.61CX Basic pKa: 5.71CX LogP: 1.86CX LogD: 1.83Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.69Np Likeness Score: -1.80
References 1. (2021) Isoxazole derivatives targeting tacc3 as anticancer agents,